CA3214545A1 - Beta-casein a2 and reducing or preventing symptoms of lactose intolerance - Google Patents

Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Info

Publication number
CA3214545A1
CA3214545A1 CA3214545A CA3214545A CA3214545A1 CA 3214545 A1 CA3214545 A1 CA 3214545A1 CA 3214545 A CA3214545 A CA 3214545A CA 3214545 A CA3214545 A CA 3214545A CA 3214545 A1 CA3214545 A1 CA 3214545A1
Authority
CA
Canada
Prior art keywords
beta
casein
milk
lactose
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214545A
Other languages
English (en)
French (fr)
Inventor
Andrew John CLARKE
Malav Suchin TRIVEDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A2 Milk Co Ltd
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3214545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of CA3214545A1 publication Critical patent/CA3214545A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Peptides Or Proteins (AREA)
CA3214545A 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance Pending CA3214545A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845480P 2013-07-12 2013-07-12
US61/845,480 2013-07-12
CA2917492A CA2917492C (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2917492A Division CA2917492C (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Publications (1)

Publication Number Publication Date
CA3214545A1 true CA3214545A1 (en) 2015-01-15

Family

ID=52280344

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3214545A Pending CA3214545A1 (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
CA2917492A Active CA2917492C (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2917492A Active CA2917492C (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Country Status (20)

Country Link
US (3) US20160136238A1 (https=)
EP (2) EP3542805A1 (https=)
JP (2) JP6436592B2 (https=)
KR (2) KR102367941B1 (https=)
CN (3) CN110800803A (https=)
AU (2) AU2014287862B2 (https=)
BR (1) BR112016000612B8 (https=)
CA (2) CA3214545A1 (https=)
CL (1) CL2016000064A1 (https=)
DK (1) DK3019180T3 (https=)
ES (1) ES2743194T3 (https=)
IL (2) IL243366B (https=)
MX (2) MX368912B (https=)
MY (2) MY190309A (https=)
NZ (2) NZ754642A (https=)
PH (2) PH12016500032B1 (https=)
RU (1) RU2671562C2 (https=)
SG (2) SG10201710237PA (https=)
WO (1) WO2015005804A1 (https=)
ZA (1) ZA201600007B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
JP7137745B2 (ja) * 2015-05-22 2022-09-15 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼインａ２および抗酸化能
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function
JP6873234B2 (ja) * 2016-09-30 2021-05-19 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および腸微生物叢
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
EP4377480A4 (en) * 2021-07-30 2025-09-24 Active Genomes Expressed Diagnostics Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND LIVER DISEASE
AU2024262008A1 (en) * 2023-04-25 2025-11-13 The A2 Milk Company Limited Beta-caseins in infant milk formula and use for reducing crying episodes in infants
WO2024225919A1 (en) * 2023-04-25 2024-10-31 The A2 Milk Company Limited Beta-caseins in infant milk formula and use for reducing regurgitation episodes in infants
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
CN117322466A (zh) * 2023-11-02 2024-01-02 光明乳业股份有限公司 一种新型婴幼儿食用的发酵乳及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
WO1996036239A1 (en) 1995-05-16 1996-11-21 Corran Norman Stuart Mclachlan Food product and process
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
DK1663298T3 (da) * 2003-09-23 2019-10-14 Dsm Ip Assets Bv Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
CN1899054A (zh) * 2006-07-17 2007-01-24 颜贻谦 去糖牛奶的制作方法
JP2012522505A (ja) * 2009-04-03 2012-09-27 ネステク ソシエテ アノニム ミルク様飲料
AU2010238184B2 (en) * 2009-04-15 2014-09-04 Glanbia Nutritionals (Ireland) Limited A reduced lactose milk product and a process for the preparation thereof
DE102010009582A1 (de) * 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
MX389785B (es) * 2011-07-26 2025-03-18 Nucitec Sa De Cv Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento.
CN103315063A (zh) * 2012-03-19 2013-09-25 基斯有限公司 可预防疾病的婴儿配方奶粉
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient

Also Published As

Publication number Publication date
US20220175882A1 (en) 2022-06-09
KR102291660B1 (ko) 2021-08-19
CA2917492C (en) 2023-11-14
IL261143B (en) 2021-02-28
PH12016500032B1 (en) 2019-10-25
IL261143A (en) 2018-10-31
AU2014287862B2 (en) 2019-07-11
SG10201710237PA (en) 2018-01-30
HK1223846A1 (en) 2017-08-11
KR20200085375A (ko) 2020-07-14
RU2018131604A3 (https=) 2022-04-19
JP6436592B2 (ja) 2018-12-12
MY172939A (en) 2019-12-16
RU2015156804A3 (https=) 2018-05-31
ZA201600007B (en) 2017-11-29
AU2019203684B2 (en) 2021-08-05
ES2743194T3 (es) 2020-02-18
IL243366B (en) 2018-11-29
BR112016000612B8 (pt) 2022-02-22
SG11201510707YA (en) 2016-01-28
NZ715985A (en) 2022-09-30
AU2019203684A1 (en) 2019-06-20
AU2014287862A1 (en) 2016-02-11
CN114832092A (zh) 2022-08-02
EP3542805A1 (en) 2019-09-25
PH12019550112A1 (en) 2020-09-14
CN105431156A (zh) 2016-03-23
NZ754642A (en) 2022-09-30
PH12016500032A1 (en) 2016-03-28
MX2019012446A (es) 2020-02-03
EP3019180B1 (en) 2019-05-29
RU2671562C2 (ru) 2018-11-02
WO2015005804A1 (en) 2015-01-15
BR112016000612A2 (https=) 2017-07-25
MX368912B (es) 2019-10-21
MY190309A (en) 2022-04-13
MX2016000308A (es) 2016-11-14
BR112016000612B1 (pt) 2021-11-03
EP3019180A4 (en) 2017-03-08
CL2016000064A1 (es) 2016-12-16
DK3019180T3 (da) 2019-08-26
RU2018131604A (ru) 2018-11-20
JP2016523958A (ja) 2016-08-12
CA2917492A1 (en) 2015-01-15
JP6990154B2 (ja) 2022-01-12
RU2015156804A (ru) 2017-08-17
CN110800803A (zh) 2020-02-18
KR20160030974A (ko) 2016-03-21
US20160136238A1 (en) 2016-05-19
MX394585B (es) 2025-03-04
KR102367941B1 (ko) 2022-02-24
US20200147173A1 (en) 2020-05-14
JP2018203753A (ja) 2018-12-27
EP3019180A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
AU2019203684B2 (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
US11911439B2 (en) Beta-casein A2 and prevention of inflammation of the bowel
HK40013850A (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
HK1223846B (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
RU2791693C2 (ru) Бета-казеин а2 и уменьшение или предотвращение симптомов непереносимости лактозы
HK40013851A (en) Beta-casein a2 and prevention of inflammation of the bowel
HK1222362B (en) Composition comprising beta-casein a2 for use in the prevention of inflammation of the bowel
NZ753622B2 (en) Beta-casein a2 and prevention of inflammation of the bowel
NZ753622A (en) Beta-casein a2 and prevention of inflammation of the bowel

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230928

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250208

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250208

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260326